Search results | diabetes

Reports

Diabetes Partnering

The Diabetes Partnering provides understanding and access to the diabetes partnering deals and agreements entered into by the worlds leading healthcare companies

Insights

AstraZeneca is speculated to buy diabetes JV from Bristol

AstraZeneca may seek to increase its stake in a diabetes joint venture with Bristol-Myers Squibb, following a decision by the U.S. firm to exit diabetes drug research.

Sanofi’s potential acquisition of Bayers diabetes unit tops bio news headlines

The biggest bio news hovering the pharmaceutical market is Bayer‘s much rumored sale of its blood glucose meter business to French healthcare company Sanofi SA

Sanofi seeking pharma partners in India for cancer & diabetes drug discovery

The world’s fourth largest drug-maker, Sanofi, will tap Indian talent for its drug discovery in the field of oncology and diabetes and is looking for pharma partners to execute the same.

Is top pharma Bayer selling its diabetes unit?

Bayer, a top pharma company is considering the sale of its blood glucose meters business as it offers few synergies with its other healthcare activities

Proteonomix examines licensing of diabetes stem cell technology

Proteonomix has that it has decided to examine the possibility of licensing its stem cell diabetes related technology to another company in light of continued progress toward its trial of UMK-121, its stem cell treatment for patients awaiting liver transplant to overcome End Stage Liver Disease (“ESLD”).

Boehringer and Zealand team up to develop diabetes and obesity therapeutics

The companies have jointly announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity.

Type I diabetes therapy to be marketed in region with the highest incidence of disease

Diamyd Medical have announced a commercialization agreement with Janssen Pharma regarding their GAD65 antigen-based type I diabetes therapy.

New report: Global Autoimmune Disease Partnering 2010-2015

The Global Autoimmune Disease Partnering 2010-2015 report provides comprehensive understanding and unprecedented access to the autoimmune partnering deals and agreements entered into by the worlds leading healthcare companies

M&A news: who will win the bidding race?

M&A news: The Canadian pharma company Valeant Pharmaceuticals is rumoured to be raising money to make a bid for specialty drugmaker Salix Pharmaceuticals, according to Bloomberg, which cites people familiar with the matter.

Merger news : Actavis eyes $3 billion bid for Almirall

Merger news: Rumors that Ireland-based Actavis is still looking to buy up a company or two continue with speculation that it is considering Spanish drugmaker Almirall SA. Actavis, which is domiciled in Ireland, but operates out of Parsippany, N.J. was also earlier rumored to be interested in buying GI drugmaker Salix Pharmaceuticals and Omega Pharma NV.

Events

Sorry, your search returned no results.


Deals

MedImmune partners with Joslin for diabetes

MedImmune and Joslin Diabetes Center announced a three-year research collaboration to develop new medicines for the treatment of diabetes, obesity, and related metabolic disorders

Eli Lilly , Uni of Surrey are pharma partners for diabetes treatment

Eli, Lilly and Company pharma partners on a five-year research partnership with the University of Surrey to study health outcomes, focusing on the effects of treatment in people with type 2 diabetes, which affects about 95 percent of those with the disease.

Servier gains ITCA 650 for Type 2 diabetes

Intarcia Therapeutics announced the successful start of a strategic partnership with Servier outside the United States and Japan, to develop and commercialize ITCA 650

Big Pharma, Boehringer Ingelheim collaborates with American Diabetes Association

The American Diabetes Association announces The American Diabetes Association and Boehringer Ingelheim Research Award: Chronic Kidney Disease and Renal Insufficiency in the Setting of Diabetes.

Novo Nordisk signs pharma deal for diabetes drug

Zosano Pharma has entered into a pharma deal with Novo Nordisk to develop a new transdermal presentation of semaglutide for $155 million.

Sanofi pays a second milestone for diabetes pharma licensing deal

Sanofi paid $15 million to Zealand Pharma for approval of Phase 3 study protocol for Type 2 diabetes pharma licensing.

Tandem Diabetes in $100 IPO financing

Tandem Diabetes Care is plotting a trip to Wall Street, filing to raise $100 million in an IPO financing and join the bevy of biotech companies cashing in on a market revival

Boehringer Ingelheim pharma deals for $3.27 million of diabetes research grants

The Boehringer Ingelheim and European Foundation for the Study of Diabetes entered pharma deals to fund European-wide diabetes research.

Boehringer Ingelheim pharma partners Healthrageous and United BioSource for type 2 diabetes research collaboration

Boehringer Ingelheim, a big pharma company, have entered deals with pharma partners United BioSource for type 2 diabetes research.

Roche Diagnostics big pharma deals Diabetes Care Club for Accu-Chek distribution

Roche Diagnostics enters big pharma deals with Diabetes Care Club for the distribution of Roche’s Accu-Chek.